In myocardial ischemia, the integrity of the cardiac sarcolemma is severely stressed in the critical earliest moments upon reperfusion. Bolstering sarcolemma integrity improves myocyte survival.
OVERVIEW: CARDIAC MUSCLE MEMBRANE INTEGRITY AND HEART PERFORMANCE
Cardiac muscle membrane instability is a hallmark of myocardial ischemia-reperfusion (I/R) injury .
It is well-documented that in the very earliest moments of reperfusion cardiac myocytes swell markedly due to significant myoplasmic osmolyte accumulation during the ischemic period (21, 25, 28, 30, 31) . Myocyte swelling, along with myocyte contracture, exerts a severe stress on the cardiac membrane (sarcolemma), leading to membrane tears, pores, blebs, and instability (19, 20, (25) (26) (27) (28) . Loss in the primary barrier function of the cardiac membrane leads to catastrophic outcomes in terms of overall myocyte viability and function. It follows that preserving cardiac sarcolemma integrity in I/R holds promise for enhancing cardiac muscle viability thus improving overall heart function during reperfusion ( Figure 1 ).
Myocardial I/R causes millions of deaths per year (2, 10, 15, 17, 19, (32) (33) (34) (35) (36) (37) (38) (39) underscoring the urgency for detailed understanding. There are multiple pathological pathways to cardiac reperfusion injury;
nonetheless, in the face of this complexity, a key unifying component of I/R injury centers on cardiac muscle membrane instability (19) (20) (21) (23) (24) (25) (26) 29, 31, 37, 40) . In cardiac I/R, sarcolemmal rupture and necrotic cell death are well documented in the critical minutes of reperfusion after an ischemic event (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . Whereas the pathways leading to cardiac I/R injury are multifold and complex (18, 41, 42) , we and others have established a sound premise that a clear approach for a clinically meaningful treatment would be one that would directly enhance cardiac membrane stability in I/R (43) . Given that cardiac sarcolemma damage is a well-established hallmark of I/R injury, it is surprising this has received relatively little direct investigation as a possible target for I/R treatment development (44) .
In this review, we detail the design and implementation of chemical-based synthetic muscle membrane stabilizers for the diseased heart (Central Illustration). Muscle membrane stabilizers target and interface with, but do not transit across, the cell outer membrane to confer sarcolemma stabilization ( Figure 2 ) (45) (46) (47) . We recently showed in several genetic models of cardiac muscle membrane instability that synthetic block copolymer-based membrane stabilizers prevent progressive cardiomyopathy (48, 49) . We focus here on the mechanism by which block copolymer muscle membrane stabilizers interface with the sarcolemma to preserve cardiac myocyte viability. A structurefunction approach is enabled by leveraging insights across disciplinary lines, extending from chemistry to physiology and cardiology. Collectively, we advance synthetic membrane stabilizers as a unique first-inclass cell extrinsic strategy for directly protecting cardiac muscle membranes during I/R in vivo (48) (49) (50) (51) (52) (53) .
We propose that membrane stabilizers, in the form of synthetic copolymers, provide a unique tool to investigate the mechanism of cardiac I/R injury and provide a template toward developing novel therapies designed to stabilize the muscle membrane in acquired heart disease. Thus, this review is centered on novel means and mechanisms to preserve viable myocardium during reperfusion.
THE CARDIAC MEMBRANE AS A DIRECT THERAPEUTIC TARGET IN MYOCARDIAL I/R
Cardiac I/R injury exacts a tremendous toll on morbidity and mortality in humans (54) (55) (56) (57) (58) (59) , and recent clinical cardioprotective trials have been disappointing (60) . The hypothesis advanced here is that during the critical earliest stages of I/R the cardiac myocyte's endogenous membrane stabilization/ repair machinery is overwhelmed and that synthetic copolymers serve to rapidly stabilize the membrane as a bridging mechanism. In this way, copolymers permit the cell intrinsic membrane repair pathways adequate time to fully repair the damaged membrane and preserve cardiac myocyte viability in vivo. Block copolymers offer a direct approach to preserve membrane integrity in I/R, thereby representing a novel therapeutic development opportunity with the potential for high clinical impact.
FI GURE 1 Health Relevance
Clinically relevant pathways to cardiac reperfusion injury with focus on cardiac membrane instability and the novel use of synthetic membrane stabilizers. CPR ¼ cardiopulmonary resuscitation; MI ¼ myocardial infarction.
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Heart muscle has multiple cell intrinsic/endogenous mechanisms to stabilize/repair the fragile/ damaged sarcolemma during stress (61) (62) (63) (64) On the physiological timescale, the myocyte's intrinsic membrane repair and stabilization pathways, including dysferlin, mitsugumin 53, Thbs4, and others, can take up to several minutes or longer to repair sarcolemma damage (61, (74) (75) (76) (77) . In I/R, this delay in repair can be catastrophic, leading to the demise of the cell. To address this, we and others have pursued cell-extrinsic synthetic chemistries as a rapid means to protect damaged striated muscle membranes (Figures 1 to 3 ). We were the first to
show that the first-in-class synthetic membrane stabilizer, triblock copolymer poloxamer 188 (P188), Overarching goal: stabilizing the cardiac muscle membrane in disease using synthetic chemistry.
A P R I L 2 0 1 9 : 2 7 5 -8 7
Cardiac Muscle Membrane Stabilization
MYOCARDIAL I/R INJURY CLINICAL FEATURES
Coronary heart disease is the most common form of human heart disease in the United States, accounting for 20% of all deaths (82) . Coronary heart disease most often presents as a myocardial infarction (MI), during which cardiac tissue becomes ischemic due to coronary arterial blockage, and this blockage must be rapidly reversed to help preserve functional heart muscle (4, 30, 33, 34, 36, 37, (83) (84) (85) (86) (87) (88) . In the United States, Houang et al.
Cardiac Muscle Membrane Stabilization P188 has also been used as an additive enhancing blood oxygenation, cardiopulmonary bypass, in heartlung bypass, and as a rheological agent to lessen blood viscosity and platelet aggregation (124) (125) (126) (127) (128) (129) .
Of direct relevance to STEMI and I/R injury, a previous study showed that intravenous injection of A recent investigation further showed that cardiac I/R injury, which is significantly amplified in animal models of sarcolemmal loss-of-function, was abrogated by application of copolymer-based membrane stabilizers (42) . P188 treatment of rat cardiac myocytes exposed to simulated ischemia/reperfusion in vitro prevented membrane leakage of intracellular lactate dehydrogenase. Furthermore, P188 mediated Houang et al.
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THE COPOLYMER-MEMBRANE INTERFACE: TOWARD THE MECHANISM OF MUSCLE MEMBRANE STABILIZATION
It has been established that block copolymer molecular design impacts molecular interaction with phospholipid membranes and this, in turn, significantly affects muscle membrane stabilization efficacy (50) (51) (52) (53) 139) . From a structure-function perspective, there is a significant opportunity to gain mechanistic insights with the long-range goal to improve and optimize membrane stabilization properties of block Table 1) There is a significant opportunity to advance mechanistic insights and enhanced performance into how copolymers function as membrane stabilizers.
To date, structure-function and efficacy studies have 
